Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making

Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.

Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 …

/by

Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making

Holzkirchen, 29 April, 2016 – Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.

Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 …

/by

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit’s® nephrology indication

  • Sandoz’ epoetin alfa product offering has already generated more than 400,0001 patient years of experience worldwide

  • EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication*.

“By expanding our …

/by